Regencell Bioscience (NASDAQ:RGC) Sees Strong Trading Volume – Should You Buy?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) saw unusually-high trading volume on Thursday . 245,923 shares were traded during trading, a decline of 19% from the previous session’s volume of 304,867 shares.The stock last traded at $7.6750 and had previously closed at $8.03.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Regencell Bioscience Price Performance

The stock’s fifty day moving average is $21.80 and its 200 day moving average is $25.39.

Regencell Bioscience (NASDAQ:RGC) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.00) EPS for the quarter.

Hedge Funds Weigh In On Regencell Bioscience

Several large investors have recently modified their holdings of the stock. Squarepoint Ops LLC purchased a new stake in Regencell Bioscience during the 2nd quarter valued at $1,701,000. BNP Paribas Financial Markets bought a new position in Regencell Bioscience during the second quarter valued at $768,000. XTX Topco Ltd bought a new position in Regencell Bioscience during the third quarter valued at $598,000. Vident Advisory LLC raised its stake in shares of Regencell Bioscience by 65.7% in the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after acquiring an additional 11,866 shares during the period. Finally, Bank of America Corp DE raised its stake in shares of Regencell Bioscience by 59,113.8% in the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after acquiring an additional 17,143 shares during the period. Institutional investors own 0.13% of the company’s stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.